Soligenix Inc. (NASDAQ: SNGX) has announced encouraging interim results from its ongoing investigator-initiated study of HyBryte(TM), a potential treatment for early-stage cutaneous T-cell lymphoma (CTCL). The study, led by Ellen Kim, MD, director of the Penn Cutaneous Lymphoma Program, indicates promising success rates for patients with limited treatment options. With no new FDA-approved, skin-directed therapies introduced in over a decade, HyBryte(TM) represents a significant advancement in the field.
The interim results from the open-label study, which evaluates extended HyBryte(TM) therapy administered twice weekly for up to 54 weeks, showed positive outcomes at the 18-week evaluation point. This development is particularly noteworthy given the risks associated with conventional treatment options for CTCL patients. The study's findings, shared in collaboration with the Cutaneous Lymphoma Foundation, highlight the potential of HyBryte(TM) to fill a critical gap in CTCL treatment.
For more detailed information on the study and its implications, visit https://ibn.fm/IUoEe. Investors and interested parties can find the latest updates on Soligenix Inc. at https://ibn.fm/SNGX.
